# Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

> **NCT04657666** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 68 (actual)

## Conditions studied

- Spasticity in Participants With Multiple Sclerosis

## Interventions

- **DRUG:** Nabiximols
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04657666
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-21
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-10
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657666, "Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04657666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*